People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Other Technology, Other, Computers, Healthtech, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| RiskLens, Inc. | — | Other Technology | Series B | $25.9M | $625.9M | 2017 |
| RackWare, Inc. | — | Other Technology | Series A | $20.3M | $111.0M | 2014 |
| Noodle Partners, Inc. | — | Other | Series B | $19.3M | $299.1M | 2019 |
| BA-Insight, Inc. | — | Computers | Series A | $16.5M | $149.5M | 2013 |
| Pneuron Corp. | — | Other Technology | Series A | $12.3M | $140.6M | 2013 |
| Curavit Clinical Research Corp | — | Healthtech | Series A | $11.4M | $110.8M | 2022 |
| PeopleLinx, Inc. | — | Other Technology | Seed | $8.3M | $117.9M | 2013 |
| ProtonMedia, Inc. | — | Computers | Series A | $7.6M | $33.2M | 2009 |
| Wylei, Inc. | — | Other Technology | Series A | $5.6M | $41.6M | 2016 |
| Strategikon Pharma, Inc. | — | Pharma | Seed | $3.3M | $7.0M | 2025 |
Nathanael Lentz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Nathanael Lentz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Kennedy | 1 | 23 |
| Gavin Christensen | 1 | 23 |
| Todd Pietri | 1 | 13 |
| Eric Anderson | 1 | 11 |
| Essam Abadir | 1 | 8 |
| Mourad Yesayan | 1 | 7 |
| Ron Heinz | 1 | 7 |
| Philip Eliot | 1 | 6 |
| Glen Bressner | 1 | 6 |
| Bryan Smith | 1 | 6 |
| Victor Patterson | 1 | 6 |
| George Krautzel | 1 | 5 |
| John Katzman | 1 | 5 |
| David Hanna | 1 | 4 |
| Morgan Rodd | 1 | 4 |
| Kathryn Walker | 1 | 4 |
| Michael Horn | 1 | 4 |
| Philip Moyer | 1 | 4 |
| Andrew Newcomb | 1 | 4 |
| Michael Monteiro | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.